Novation Pharmaceuticals, Knobbe Martens Olson & Bear, Novozymes Biotech, Mattingly, Stanger & Malur, The Trustees of Columbia University, The Regents of the University of California, Knobbe Martens Olson & Bear | GenomeWeb

Novation Pharmaceuticals, of New Westminster, Calif., has filed for a US Patent entitled, “Assay for identifying compounds which affect stability of mRNA.” The application relates to an assay for the identification of biologically active compounds, in particular to a reporter gene assay for the identification of compounds, which have an effect on mRNA stability. Specifically, the invention in the patent relates to a reporter gene expression system and cell lines comprising said expression system. The invention further relates to compounds which destabilize mRNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.